Background
Gut barrier dysfunction contributes to several gastrointestinal
disorders, including colorectal cancer, but factors associated with
intestinal hyperpermeability have been minimally studied in humans.
Methods
We tested the effects of two doses of calcium (1.0 or 2.0 g/d) on
circulating biomarkers of gut permeability (anti-flagellin and
anti-lipopolysaccharide [LPS] immunoglobulins [Igs], measured via ELISA)
over a 4-month treatment period among colorectal adenoma patients in a
randomized, double-blinded, placebo-controlled clinical trial (n = 193), and
evaluated factors associated with baseline levels of these biomarkers.
Results
Baseline concentrations of anti-flagellin IgA and anti-LPS IgA were,
respectively, statistically significantly proportionately higher by 11.8%
and 14.1% among men, 31.3% and 39.8% among those with a body mass index
(BMI) ≥ 35 kg/m2, and 19.9% and 22.0% among those in the
upper relative to the lowest sex-specific tertile of waist circumference. A
combined permeability score (the summed optical densities of all four
biomarkers) was 24.3% higher among women in the upper tertile of plasma
C-reactive protein (ptrend < 0.01). We found no
appreciable effects of supplemental calcium on anti-flagellin or anti-LPS
Igs.
Conclusion
Our results suggest that 1) men and those with higher adiposity may
have greater gut permeability, 2) gut permeability and systemic inflammation
may be directly associated with one another, and 3) supplemental calcium may
not modify circulating levels of gut permeability biomarkers within four
months.
Impact
Our findings may improve understanding of the factors that influence
gut permeability to inform development of treatable biomarkers of risk for
colorectal cancer and other health outcomes.